Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308198 | 0.96 | TERT (0.40) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL29308374 | 0.94 | TERT (0.39) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL22018478 | 0.94 | TERT (0.41) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL29308375 | 0.92 | KEAP1 (0.38) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL22019122 | 0.89 | TERT (0.40) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL22019453 | 0.88 | TERT (0.42) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL29308671 | 0.87 | TERT (0.41) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL29308397 | 0.87 | TERT (0.39) | TERTPRCPDPP7MEN1KMT2A | |
| SCHEMBL22922937 | 0.85 | KEAP1 (0.40) | TERTKEAP1CALCRLAVPR2OXTR | |
| SCHEMBL29914541 | 0.85 | MEN1 (0.42) | TERTPRCPDPP7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | TERT 3410/4885PRCP 109/4885DPP7 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.